Serge Bohbot
Research Subjects
Serge Bohbot has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Laetitia Thomassin
Global Medical Affairs, Laboratoires Urgo, Paris, France
2 shared publications Sylvie Meaume
Head of Geriatric and Wound Care Department, Rothschild University Hospital, Paris, France
2 shared publicationsA. Alliez
Plastic and Reconstructive Surgery, University Hospital La Conception, APHM, 264, Rue Saint-Pierre, 13385, Marseille, France
1 shared publication- Abigail E. Chaffin
Department of Surgery, Tulane University School of Medicine, LA, US
1 shared publication - Alisha Oropallo
Department of Vascular Surgery, Comprehensive Wound Healing Center and Hyperbarics, Northwell Health; NY, US
1 shared publication Almudena Cecilia Matilla
Diabetic Foot Unit, Ramón y Cajal University Hospital, Madrid, Spain
1 shared publication
Latest Publications
- 2 October 2026
- Published by Mark Allen Group in Journal of Wound Care
- Vol. 35 (10) , 887
Safety and cost-effectiveness of a pure hypochlorous acid cleansing solution in wounds and non-intact skin management: a narrative review
Objective: Wound cleansing is an essential part of wound bed preparation and its importance in wound management is supported by numerous international guidelines and consensus documents. Cleansing solutions are used by healthcare professionals for wounds and non-intact skin. However, some of these solutions may not be effective in addressing the condition of the wound or safe enough to be used in certain patients due to the solution's potential for irritation or toxicity. According to guidelines, solution of pure hypochlorous acid (pHA; free of hypochlorite derivatives) provides a good balance between safety and efficacy. This narrative review discusses the clinical evidence available on the use of a pHA solution (Vashe Wound Solution; Urgo Medical North America, US) formulated at 330ppm with a tightly controlled, slightly acidic pH (pH 3.5–5.5). Method: A literature search of the Embase, MEDLINE, Google Scholar and TRIP databases was conducted (firstly in December 2025 and updated in June 2026), for original clinical studies reporting the use of the pHA solution, including randomised controlled trials, comparative studies, observational studies, case series/reports and health economic evaluations. Outcomes relating to efficacy, safety, tolerability, acceptability and costs were synthesised narratively. Results: A total of 56 publications were identified and included in the analysis. These clinical evaluations analysed the data of 2968 wounds in 2682 patients, including 140 preterm infants, neonates and children. The treated indications were wounds presenting with risk or clinical signs of local infection, infected wounds, skin tissue or mucosa, including wounds at debridement stage or requiring thorough cleansing, and patients with fragile, immature or non-intact skin. Across the different studies, consistent and concordant outcomes were noted, with a favourable benefit/risk profile of the solution, regardless of the method of application, treated indications and patient populations. Cleansing with the pHA solution, using soaked gauze or different irrigation techniques, to remove debris, slough and foreign bodies from the wound and skin, was found to significantly reduce bacterial growth compared to saline, soap and water, or standard of care, resulting in fewer wound-related complications. The cleanser solution also appeared to facilitate wound debridement, promote wound healing and be cost-effective in numerous indications. The safety profile of the pHA solution was ‘very good’, and no complication related to its use was reported in any of the clinical evaluations, including in preterm infants. Conclusion: The clinical evidence identified in this review consistently supported the pHA solution with a slightly acidic pH as a useful option in the management of wounds and non-intact skin, aligned with its intended use, particularly in situations where infection control and tissue tolerability are important considerations. Conducting additional high-quality comparative studies would be worthwhile to strengthen the available evidence.
- 2 October 2026
- Published by Mark Allen Group in Journal of Wound Care
- Vol. 35 (10) , 887
Safety and cost-effectiveness of a pure hypochlorous acid cleansing solution in wounds and non-intact skin management: a narrative review
Objective: Wound cleansing is an essential part of wound bed preparation and its importance in wound management is supported by numerous international guidelines and consensus documents. Cleansing solutions are used by healthcare professionals for wounds and non-intact skin. However, some of these solutions may not be effective in addressing the condition of the wound or safe enough to be used in certain patients due to the solution's potential for irritation or toxicity. According to guidelines, solution of pure hypochlorous acid (pHA; free of hypochlorite derivatives) provides a good balance between safety and efficacy. This narrative review discusses the clinical evidence available on the use of a pHA solution (Vashe Wound Solution; Urgo Medical North America, US) formulated at 330ppm with a tightly controlled, slightly acidic pH (pH 3.5–5.5). Method: A literature search of the Embase, MEDLINE, Google Scholar and TRIP databases was conducted (firstly in December 2025 and updated in June 2026), for original clinical studies reporting the use of the pHA solution, including randomised controlled trials, comparative studies, observational studies, case series/reports and health economic evaluations. Outcomes relating to efficacy, safety, tolerability, acceptability and costs were synthesised narratively. Results: A total of 56 publications were identified and included in the analysis. These clinical evaluations analysed the data of 2968 wounds in 2682 patients, including 140 preterm infants, neonates and children. The treated indications were wounds presenting with risk or clinical signs of local infection, infected wounds, skin tissue or mucosa, including wounds at debridement stage or requiring thorough cleansing, and patients with fragile, immature or non-intact skin. Across the different studies, consistent and concordant outcomes were noted, with a favourable benefit/risk profile of the solution, regardless of the method of application, treated indications and patient populations. Cleansing with the pHA solution, using soaked gauze or different irrigation techniques, to remove debris, slough and foreign bodies from the wound and skin, was found to significantly reduce bacterial growth compared to saline, soap and water, or standard of care, resulting in fewer wound-related complications. The cleanser solution also appeared to facilitate wound debridement, promote wound healing and be cost-effective in numerous indications. The safety profile of the pHA solution was ‘very good’, and no complication related to its use was reported in any of the clinical evaluations, including in preterm infants. Conclusion: The clinical evidence identified in this review consistently supported the pHA solution with a slightly acidic pH as a useful option in the management of wounds and non-intact skin, aligned with its intended use, particularly in situations where infection control and tissue tolerability are important considerations. Conducting additional high-quality comparative studies would be worthwhile to strengthen the available evidence.
- 2 January 2026
- Published by Mark Allen Group in Journal of Wound Care
- Vol. 35 (1) , 4-14
Multicomponent reduced compression therapy and TLC-NOSF dressings in leg ulcers with or without arterial component
Objective: This study was performed to assess the clinical performance of a multicomponent reduced compression system (applying ~20mmHg) and dressings based on lipido-colloid technology with nano-oligosaccharide factor (TLC-NOSF) in the management of patients with venous leg ulcers (VLUs) and mixed leg ulcers (MLUs with arterial component). Method: A prospective, multicentre, non-comparative clinical trial was conducted in the Angiology and Vascular Surgery Units in three hospitals in Madrid, Spain. Adults with VLUs or MLUs, confirmed by an ankle–brachial pressure index >0.6, were treated with UrgoK2 Lite Latex Free and UrgoStart dressings (both Laboratoires Urgo, France) for 12 weeks. The primary endpoint was complete ulcer closure by week 12. Secondary endpoints included time-to-heal, change in wound area, leg oedema resolution, change in ankle circumference, ease of application and adherence to compression therapy, adverse events (AEs), and acceptability of the treatment strategy. Results: A total of 45 patients with LUs (mean age 70.0 years; 64% male; 44% obese) were included. Based on vascular assessment, 24 patients had VLUs and 21 had MLUs, associated with leg oedema in 89% of cases. The LUs were recurrent in 60% of cases, and lasted ≥6 months in 58% of cases. The wound areas were relatively large (median value: 9.4cm 2 , interquartile range (IQR): 5.9–11.8cm 2 ), and mostly covered by sloughy tissue. Impaired perilesional skin was reported in 93% of patients. By the final visit, 71% of VLUs had healed, 25% had improved and 4% remained unchanged. Despite an initial poorer healing prognosis than for VLUs, 43% of MLUs healed and 43% improved. The median time-to-heal was nine weeks (IQR: 6–11 weeks), with no relevant difference between the two types of leg ulcer (LU). These good healing progressions were also supported by consistent and steady reductions in wound surface area throughout the 12 weeks of treatment, regardless of LU aetiology, resulting in a relative wound area reduction of 100% (median value; IQR: 93.8–100.0%) in VLUs and 98.6% (median value; IQR: 55.6–100.0%) in MLUs. Leg oedema resolved in all patients by week 8 (except two missing data), while mean ankle circumference reduced from 24.5±2.7cm at baseline to 21.4±2.4cm at final measurement. The application of the compression system was judged ‘very easy’ in 85% of cases and ‘easy’ in 15%. Full adherence to compression therapy was reported in 80% of patients during the first weeks of treatment and increased to 97% by week 8. Only two AEs, unrelated to the evaluated treatments, were reported throughout the study period. At the final visit, the association of the multicomponent reduced compression system and TLC-NOSF dressings in the management of VLUs and MLUs was considered ‘very satisfactory’ in 98% of cases and ‘satisfactory’ in 2% by the healthcare professionals involved in this study. Conclusion: The association of multicomponent reduced compression treatment and TLC-NOSF dressings resulted in high rates of wound healing, leg oedema resolution, good adherence and tolerance. These findings support the use of the evaluated strategy in patients with VLUs or MLUs. Multicomponent reduced compression therapy could facilitate the early implementation of effective compression therapy in patients who are unable to tolerate strong compression or for whom it is contraindicated.
- 2 January 2026
- Published by Mark Allen Group in Journal of Wound Care
- Vol. 35 (1) , 4-14
Multicomponent reduced compression therapy and TLC-NOSF dressings in leg ulcers with or without arterial component
Objective: This study was performed to assess the clinical performance of a multicomponent reduced compression system (applying ~20mmHg) and dressings based on lipido-colloid technology with nano-oligosaccharide factor (TLC-NOSF) in the management of patients with venous leg ulcers (VLUs) and mixed leg ulcers (MLUs with arterial component). Method: A prospective, multicentre, non-comparative clinical trial was conducted in the Angiology and Vascular Surgery Units in three hospitals in Madrid, Spain. Adults with VLUs or MLUs, confirmed by an ankle–brachial pressure index >0.6, were treated with UrgoK2 Lite Latex Free and UrgoStart dressings (both Laboratoires Urgo, France) for 12 weeks. The primary endpoint was complete ulcer closure by week 12. Secondary endpoints included time-to-heal, change in wound area, leg oedema resolution, change in ankle circumference, ease of application and adherence to compression therapy, adverse events (AEs), and acceptability of the treatment strategy. Results: A total of 45 patients with LUs (mean age 70.0 years; 64% male; 44% obese) were included. Based on vascular assessment, 24 patients had VLUs and 21 had MLUs, associated with leg oedema in 89% of cases. The LUs were recurrent in 60% of cases, and lasted ≥6 months in 58% of cases. The wound areas were relatively large (median value: 9.4cm 2 , interquartile range (IQR): 5.9–11.8cm 2 ), and mostly covered by sloughy tissue. Impaired perilesional skin was reported in 93% of patients. By the final visit, 71% of VLUs had healed, 25% had improved and 4% remained unchanged. Despite an initial poorer healing prognosis than for VLUs, 43% of MLUs healed and 43% improved. The median time-to-heal was nine weeks (IQR: 6–11 weeks), with no relevant difference between the two types of leg ulcer (LU). These good healing progressions were also supported by consistent and steady reductions in wound surface area throughout the 12 weeks of treatment, regardless of LU aetiology, resulting in a relative wound area reduction of 100% (median value; IQR: 93.8–100.0%) in VLUs and 98.6% (median value; IQR: 55.6–100.0%) in MLUs. Leg oedema resolved in all patients by week 8 (except two missing data), while mean ankle circumference reduced from 24.5±2.7cm at baseline to 21.4±2.4cm at final measurement. The application of the compression system was judged ‘very easy’ in 85% of cases and ‘easy’ in 15%. Full adherence to compression therapy was reported in 80% of patients during the first weeks of treatment and increased to 97% by week 8. Only two AEs, unrelated to the evaluated treatments, were reported throughout the study period. At the final visit, the association of the multicomponent reduced compression system and TLC-NOSF dressings in the management of VLUs and MLUs was considered ‘very satisfactory’ in 98% of cases and ‘satisfactory’ in 2% by the healthcare professionals involved in this study. Conclusion: The association of multicomponent reduced compression treatment and TLC-NOSF dressings resulted in high rates of wound healing, leg oedema resolution, good adherence and tolerance. These findings support the use of the evaluated strategy in patients with VLUs or MLUs. Multicomponent reduced compression therapy could facilitate the early implementation of effective compression therapy in patients who are unable to tolerate strong compression or for whom it is contraindicated.
- 2 July 2023
- Published by Mark Allen Group in Journal of Wound Care
- Vol. 32 (7) , 402-410
Healico—a wound care assistant in your pocket
Non-optimal wound management and late referral to specialised units negatively impacts patient prognosis and quality of life, as well as healthcare costs. Healico is a new mobile application (app), created in the wound care field, in response to the challenges and difficulties encountered by health professionals (HPs) who deal with patients with wounds on a daily basis. This article aims to describe how this new app was developed, how it works, as well as the real-life clinical benefits and evidence supporting its use. The Healico App assists nurses, physicians and other HPs by: supporting a holistic approach to patient management; facilitating wound assessment and documentation, irrespective of where care is provided (primary, specialised or hospital services, in either public or private institutions); and supporting consistent and safe clinical practice, as well as reducing variation in care. It also provides a fast, fluid and secure communication channel, and effective coordination between HPs, supporting early interventions. The app has also been shown to improve therapeutic adherence of patients by promoting inclusive dialogue with them. Declaration of interest: This article is supported by Laboratoires Urgo, France. SB is an employee of Laboratoires Urgo. SM, PV, AF and LS provide advisory and/or speaking services to pharmaceutical and other healthcare organisations including, but not limited to, Laboratoires Urgo.
- 2 July 2023
- Published by Mark Allen Group in Journal of Wound Care
- Vol. 32 (7) , 402-410
Healico—a wound care assistant in your pocket
Non-optimal wound management and late referral to specialised units negatively impacts patient prognosis and quality of life, as well as healthcare costs. Healico is a new mobile application (app), created in the wound care field, in response to the challenges and difficulties encountered by health professionals (HPs) who deal with patients with wounds on a daily basis. This article aims to describe how this new app was developed, how it works, as well as the real-life clinical benefits and evidence supporting its use. The Healico App assists nurses, physicians and other HPs by: supporting a holistic approach to patient management; facilitating wound assessment and documentation, irrespective of where care is provided (primary, specialised or hospital services, in either public or private institutions); and supporting consistent and safe clinical practice, as well as reducing variation in care. It also provides a fast, fluid and secure communication channel, and effective coordination between HPs, supporting early interventions. The app has also been shown to improve therapeutic adherence of patients by promoting inclusive dialogue with them. Declaration of interest: This article is supported by Laboratoires Urgo, France. SB is an employee of Laboratoires Urgo. SM, PV, AF and LS provide advisory and/or speaking services to pharmaceutical and other healthcare organisations including, but not limited to, Laboratoires Urgo.
- Open Access
- 1 March 2023
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery - Global Open
- Vol. 11 (3) , e4866
Postabdominoplasty Scar Improvement after a Single Session with an Automated 1210-nm Laser
Background: Abdominoplasty, one of the most commonly performed aesthetic procedures, aims at correcting excess abdominal skin and fat, but generates a long abdominal scar. The efficacy of an automated portative 1210-nm laser in improving the appearance of surgical scars has been previously demonstrated in a double-blind randomized controlled trial. The purpose of this work was to document the use of this laser in real-life practice. Methods: Eighteen patients undergoing abdominoplasty and treated with the evaluated laser (UrgoTouch, Laboratoires Urgo; one single session immediately after the surgery) were included in this prospective, mono-center, observational study. Change in scar characteristics was assessed using the validated Observer Scar Assessment Scale, and the patients’ and surgeon’s satisfaction was rated using a four-point scale. Results: The aesthetic outcome of the scars was very positive with a mean Observer Scar Assessment Scale score of 17.0 (SD 4.6) and 14.4 (SD 3.8) on the 6–60 point scale (60: the worst possible outcome) at 6 and 12 months, respectively. A high degree of satisfaction was also expressed by both surgeon and patients at 6 weeks, 6 months, and 12 months. No laser-related incident was reported during the study, including in patients with darker phototypes. Conclusions: These findings seem to be consistent with previous clinical evidence on the use of this laser on fresh incisions. The high degree of satisfaction reported by both surgeon and patients seems to comfort the benefits of this procedure at short- and long-term and support the use of this laser in daily practice of plastic surgery.
- 1 March 2023
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery - Global Open
- Vol. 11 (3) , e4866
Open AccessPostabdominoplasty Scar Improvement after a Single Session with an Automated 1210-nm Laser
Background: Abdominoplasty, one of the most commonly performed aesthetic procedures, aims at correcting excess abdominal skin and fat, but generates a long abdominal scar. The efficacy of an automated portative 1210-nm laser in improving the appearance of surgical scars has been previously demonstrated in a double-blind randomized controlled trial. The purpose of this work was to document the use of this laser in real-life practice. Methods: Eighteen patients undergoing abdominoplasty and treated with the evaluated laser (UrgoTouch, Laboratoires Urgo; one single session immediately after the surgery) were included in this prospective, mono-center, observational study. Change in scar characteristics was assessed using the validated Observer Scar Assessment Scale, and the patients’ and surgeon’s satisfaction was rated using a four-point scale. Results: The aesthetic outcome of the scars was very positive with a mean Observer Scar Assessment Scale score of 17.0 (SD 4.6) and 14.4 (SD 3.8) on the 6–60 point scale (60: the worst possible outcome) at 6 and 12 months, respectively. A high degree of satisfaction was also expressed by both surgeon and patients at 6 weeks, 6 months, and 12 months. No laser-related incident was reported during the study, including in patients with darker phototypes. Conclusions: These findings seem to be consistent with previous clinical evidence on the use of this laser on fresh incisions. The high degree of satisfaction reported by both surgeon and patients seems to comfort the benefits of this procedure at short- and long-term and support the use of this laser in daily practice of plastic surgery.
- Open Access
- 29 January 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (3) , 1040
Microcirculation Improvement in Diabetic Foot Patients after Treatment with Sucrose Octasulfate-Impregnated Dressings
To assess the patients’ microcirculation evolution during the treatment with a sucrose octasulfate-impregnated dressing, fifty patients with neuroischaemic DFU treated with TLC-NOSF dressing were included in a prospective study between November 2020 and February 2022. TcpO2 values were measured on the dorsalis pedis or tibial posterior arteries’ angiosome according to the ulcer location. TcpO2 values were assessed at day 0 and every 4 weeks during 20 weeks of the follow-up or until the wound healed. A cut-off point of tcpO2 < 30 mmHg was defined for patients with impaired microcirculation. The TcpO2 values showed an increase between day 0 and the end of the study, 33.04 ± 12.27 mmHg and 40.89 ± 13.06 mmHg, respectively, p < 0.001. Patients with impaired microcirculation showed an increase in the tcpO2 values from day 0 to the end of the study (p = 0.023). Furthermore, we observed a significant increase in the TcpO2 values in the forefoot DFU (p = 0.002) and in the rearfoot DFU (p = 0.071), with no difference between the ulcer locations (p = 0.694). The local treatment with TLC-NOSF dressing improved the microcirculation in patients with neuroischaemic DFU, regardless of microcirculation status at the baseline, and in the forefoot, regardless of the location.
- 29 January 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (3) , 1040
Open AccessMicrocirculation Improvement in Diabetic Foot Patients after Treatment with Sucrose Octasulfate-Impregnated Dressings
To assess the patients’ microcirculation evolution during the treatment with a sucrose octasulfate-impregnated dressing, fifty patients with neuroischaemic DFU treated with TLC-NOSF dressing were included in a prospective study between November 2020 and February 2022. TcpO2 values were measured on the dorsalis pedis or tibial posterior arteries’ angiosome according to the ulcer location. TcpO2 values were assessed at day 0 and every 4 weeks during 20 weeks of the follow-up or until the wound healed. A cut-off point of tcpO2 < 30 mmHg was defined for patients with impaired microcirculation. The TcpO2 values showed an increase between day 0 and the end of the study, 33.04 ± 12.27 mmHg and 40.89 ± 13.06 mmHg, respectively, p < 0.001. Patients with impaired microcirculation showed an increase in the tcpO2 values from day 0 to the end of the study (p = 0.023). Furthermore, we observed a significant increase in the TcpO2 values in the forefoot DFU (p = 0.002) and in the rearfoot DFU (p = 0.071), with no difference between the ulcer locations (p = 0.694). The local treatment with TLC-NOSF dressing improved the microcirculation in patients with neuroischaemic DFU, regardless of microcirculation status at the baseline, and in the forefoot, regardless of the location.
- Open Access
- 22 January 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (1) , e0245652
Cost-effectiveness of TLC-NOSF dressings versus neutral dressings for the treatment of diabetic foot ulcers in France
This study assesses the cost-effectiveness of Technology Lipido-Colloid with Nano Oligo Saccharide Factor (TLC-NOSF) wound dressings versus neutral dressings in the management of diabetic foot ulcers (DFUs) from a French collective perspective. We used a Markov microsimulation cohort model to simulate the DFU monthly progression over the lifetime horizon. Our study employed a mixed method design with model inputs including data from interventional and observational studies, French databases and expert opinion. The demographic characteristics of the simulated population and clinical efficacy were based on the EXPLORER double-blind randomized controlled trial. Health-related quality of life, costs, and resource use inputs were taken from the literature relevant to the French context. The main outcomes included life-years without DFU (LYsw/DFU), quality-adjusted life-years (QALYs), amputations, and lifetime costs. To assess the robustness of the results, sensitivity and subgroup analyses based on the wound duration at treatment initiation were performed. Treatment with the TLC-NOSF dressing led to total cost savings per patient of EUR 35,489, associated with gains of 0.50 LYw/DFUand 0.16 QALY. TLC-NOSF dressings were established as the dominant strategy in the base case and all sensitivity analyses. Furthermore, the model revealed that, for every 100 patients treated with TLC-NOSF dressings, two amputations could be avoided. According to the subgroup analysis results, the sooner the TLC-NOSF treatment was initiated, the better were the outcomes, with the highest benefits for ulcers with a duration of two months or less (+0.65 LYw/DFU, +0.23 QALY, and cost savings of EUR 55,710). The results from the French perspective are consistent with the ones from the German and British perspectives. TLC-NOSF dressings are cost-saving compared to neutral dressings, leading to an increase in patients’ health benefits and a decrease in the associated treatment costs. These results can thus be used to guide healthcare decisionmakers. The potential savings could represent EUR 3,345 per treated patient per year and even reach EUR 4,771 when TLC-NOSF dressings are used as first line treatment. The EXPLORER trial is registered with ClinicalTrials.gov, number NCT01717183.
- 22 January 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (1) , e0245652
Open AccessCost-effectiveness of TLC-NOSF dressings versus neutral dressings for the treatment of diabetic foot ulcers in France
This study assesses the cost-effectiveness of Technology Lipido-Colloid with Nano Oligo Saccharide Factor (TLC-NOSF) wound dressings versus neutral dressings in the management of diabetic foot ulcers (DFUs) from a French collective perspective. We used a Markov microsimulation cohort model to simulate the DFU monthly progression over the lifetime horizon. Our study employed a mixed method design with model inputs including data from interventional and observational studies, French databases and expert opinion. The demographic characteristics of the simulated population and clinical efficacy were based on the EXPLORER double-blind randomized controlled trial. Health-related quality of life, costs, and resource use inputs were taken from the literature relevant to the French context. The main outcomes included life-years without DFU (LYsw/DFU), quality-adjusted life-years (QALYs), amputations, and lifetime costs. To assess the robustness of the results, sensitivity and subgroup analyses based on the wound duration at treatment initiation were performed. Treatment with the TLC-NOSF dressing led to total cost savings per patient of EUR 35,489, associated with gains of 0.50 LYw/DFUand 0.16 QALY. TLC-NOSF dressings were established as the dominant strategy in the base case and all sensitivity analyses. Furthermore, the model revealed that, for every 100 patients treated with TLC-NOSF dressings, two amputations could be avoided. According to the subgroup analysis results, the sooner the TLC-NOSF treatment was initiated, the better were the outcomes, with the highest benefits for ulcers with a duration of two months or less (+0.65 LYw/DFU, +0.23 QALY, and cost savings of EUR 55,710). The results from the French perspective are consistent with the ones from the German and British perspectives. TLC-NOSF dressings are cost-saving compared to neutral dressings, leading to an increase in patients’ health benefits and a decrease in the associated treatment costs. These results can thus be used to guide healthcare decisionmakers. The potential savings could represent EUR 3,345 per treated patient per year and even reach EUR 4,771 when TLC-NOSF dressings are used as first line treatment. The EXPLORER trial is registered with ClinicalTrials.gov, number NCT01717183.
- 3 March 2019
- Published by Mark Allen Group in Journal of Wound Care
- Vol. 28 (3) , 164-175
Evaluation of TLC-NOSF dressing with poly-absorbent fibres in exuding leg ulcers: two multicentric, single-arm, prospective, open-label clinical trials
Objective: To assess the efficacy, safety and acceptability of a new TLC-NOSF dressing with poly-absorbent fibres in the management of exuding leg ulcers, at the different stages of healing. Method: This work presents the results of two prospective, multicentric clinical studies: NEREIDES and CASSIOPEE. Patients with a non-infected, moderate-to-strongly exudating leg ulcer of venous or mixed origin, were treated with the dressing and an appropriate compression system for 12 weeks. The wounds included in NEREIDES had to be in debridement stage, and those in CASSIOPEE at granulation stage. In both studies, the primary outcome was the relative wound area reduction (RWAR) at week 12. Main secondary outcomes included healing rate, time-to-reach wound closure, adverse events and acceptability of the dressing by patients and health professionals. Results: There were 37 patients included in NEREIDES and 51 in CASSIOPEE. The two cohorts presented similar patient and wound characteristics, except from the percentage of sloughy tissue on wound bed at baseline (median: 75% NEREIDES and 30% CASSIOPEE). At week 12, the RWAR (60% NEREIDES and 81% CASSIOPEE), wound closure rates (18% NEREIDES and 20% CASSIOPEE) and mean times-to-reach wound closure (58±27 days NEREIDES and 55±23 days CASSIOPEE) supported the beneficial outcomes of the treatment in both cohorts. In patients with a wound duration ≤6 months, the wound area reduction reached 85% in NEREIDES and 81% in CASSIOPEE, highlighting the importance to initiate adequate treatment as soon as possible. The nature and frequency of the local adverse events were similar in both studies and consistent with the good safety profiles of the poly-absorbent fibres and of the TLC-NOSF dressings. The acceptability of the dressing (easy to apply, conformable and non-adherent to the wound bed at removal, with no pain or bleeding at removal) has been judged ‘very good’ or ‘good’ at each stage of the healing process, by both nursing staff and patients. Conclusion: These clinical results establish the new TLC-NOSF dressing with poly-absorbent fibres (UrgoStart Plus, Laboratoires Urgo) as an effective, safe and simple treatment for the local management of leg ulcers, at the different stages of healing and until wound closure.
- 3 March 2019
- Published by Mark Allen Group in Journal of Wound Care
- Vol. 28 (3) , 164-175
Evaluation of TLC-NOSF dressing with poly-absorbent fibres in exuding leg ulcers: two multicentric, single-arm, prospective, open-label clinical trials
Objective: To assess the efficacy, safety and acceptability of a new TLC-NOSF dressing with poly-absorbent fibres in the management of exuding leg ulcers, at the different stages of healing. Method: This work presents the results of two prospective, multicentric clinical studies: NEREIDES and CASSIOPEE. Patients with a non-infected, moderate-to-strongly exudating leg ulcer of venous or mixed origin, were treated with the dressing and an appropriate compression system for 12 weeks. The wounds included in NEREIDES had to be in debridement stage, and those in CASSIOPEE at granulation stage. In both studies, the primary outcome was the relative wound area reduction (RWAR) at week 12. Main secondary outcomes included healing rate, time-to-reach wound closure, adverse events and acceptability of the dressing by patients and health professionals. Results: There were 37 patients included in NEREIDES and 51 in CASSIOPEE. The two cohorts presented similar patient and wound characteristics, except from the percentage of sloughy tissue on wound bed at baseline (median: 75% NEREIDES and 30% CASSIOPEE). At week 12, the RWAR (60% NEREIDES and 81% CASSIOPEE), wound closure rates (18% NEREIDES and 20% CASSIOPEE) and mean times-to-reach wound closure (58±27 days NEREIDES and 55±23 days CASSIOPEE) supported the beneficial outcomes of the treatment in both cohorts. In patients with a wound duration ≤6 months, the wound area reduction reached 85% in NEREIDES and 81% in CASSIOPEE, highlighting the importance to initiate adequate treatment as soon as possible. The nature and frequency of the local adverse events were similar in both studies and consistent with the good safety profiles of the poly-absorbent fibres and of the TLC-NOSF dressings. The acceptability of the dressing (easy to apply, conformable and non-adherent to the wound bed at removal, with no pain or bleeding at removal) has been judged ‘very good’ or ‘good’ at each stage of the healing process, by both nursing staff and patients. Conclusion: These clinical results establish the new TLC-NOSF dressing with poly-absorbent fibres (UrgoStart Plus, Laboratoires Urgo) as an effective, safe and simple treatment for the local management of leg ulcers, at the different stages of healing and until wound closure.
- 23 February 2017
- Published by Springer Nature in Aesthetic Plastic Surgery
- Vol. 41 (4) , 938-948
A 1-Year Follow-Up of Post-operative Scars After the Use of a 1210-nm Laser-Assisted Skin Healing (LASH) Technology: A Randomized Controlled Trial
Background Laser therapies are used prophylactically for excessive scar formation. The Laser-Assisted Skin Healing treatment induces a controlled heat stress that promotes tissue regeneration. This comparative trial is the first to evaluate the performance of a new automated 1210-nm laser system, compatible with all Fitzpatrick scale phototypes. Methods Forty women undergoing bilateral breast reduction were enrolled in this double-blinded randomized controlled trial. The horizontal sutured incision of one breast was treated with the portable 1210-nm laser while in the operating theatre. The other breast was used as the study control. Objective measurements, subjective clinical assessments and safety evaluation were carried out over 1 year by both clinicians and patients. Results Six weeks following surgery, better overall appearance and modified OSAS scores were reported for the laser-treated scars when compared to the control group (p = 0.024 and p = 0.079). This supports an early effect of the laser treatment during the inflammatory stage of the healing process. After a post-treatment period of 6 months, there continued to be a strong tendency in favour of the laser treatment based on the subjective scores and corroborated by the objective improvement of the treated scar volume (p = 0.038). At 1 year, the laser-treated scars continued to improve compared to the control ones in terms of volume (p = 0.004), surface (p = 0.017) and roughness (p = 0.002), and these comparatively better results were strengthened with the blind expression of patients’ preference for their laser-treated scar (p = 0.025). Conclusions This new 1210-nm laser treatment, used as a single session performed immediately after surgery, provides significant objective and subjective improvements in scar appearance. These data can be useful when preparing patients to undergo their surgical procedure. Level of Evidence I This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.
- 23 February 2017
- Published by Springer Nature in Aesthetic Plastic Surgery
- Vol. 41 (4) , 938-948
A 1-Year Follow-Up of Post-operative Scars After the Use of a 1210-nm Laser-Assisted Skin Healing (LASH) Technology: A Randomized Controlled Trial
Background Laser therapies are used prophylactically for excessive scar formation. The Laser-Assisted Skin Healing treatment induces a controlled heat stress that promotes tissue regeneration. This comparative trial is the first to evaluate the performance of a new automated 1210-nm laser system, compatible with all Fitzpatrick scale phototypes. Methods Forty women undergoing bilateral breast reduction were enrolled in this double-blinded randomized controlled trial. The horizontal sutured incision of one breast was treated with the portable 1210-nm laser while in the operating theatre. The other breast was used as the study control. Objective measurements, subjective clinical assessments and safety evaluation were carried out over 1 year by both clinicians and patients. Results Six weeks following surgery, better overall appearance and modified OSAS scores were reported for the laser-treated scars when compared to the control group (p = 0.024 and p = 0.079). This supports an early effect of the laser treatment during the inflammatory stage of the healing process. After a post-treatment period of 6 months, there continued to be a strong tendency in favour of the laser treatment based on the subjective scores and corroborated by the objective improvement of the treated scar volume (p = 0.038). At 1 year, the laser-treated scars continued to improve compared to the control ones in terms of volume (p = 0.004), surface (p = 0.017) and roughness (p = 0.002), and these comparatively better results were strengthened with the blind expression of patients’ preference for their laser-treated scar (p = 0.025). Conclusions This new 1210-nm laser treatment, used as a single session performed immediately after surgery, provides significant objective and subjective improvements in scar appearance. These data can be useful when preparing patients to undergo their surgical procedure. Level of Evidence I This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.